Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Crossref DOI link: https://doi.org/10.1007/s40487-016-0030-2
Published Online: 2016-09-27
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Amdahl, Jordan
Chen, Lei
Delea, Thomas E.
Funding for this research was provided by:
Novartis Pharmaceuticals